Press Releases

Here is an up-to-date collection of any information given to the press. It’s a big collection, so try not to look at it all in one sitting.

Press Releases

 
Press Releases
Date Title and Summary View
Feb 17, 2006 NEW YORK, NY - February 17, 2006 - ZIOPHARM Oncology, Inc. (OTC BB: ZIOP) presented preclinical data today at the 2006 Bone Marrow Transplant Meetings in Honolulu demonstrating that ZIO-201, the Company's proprietary alkylating agent, may have a role in conditioning for bone marrow transplants. The data was presented by Lee Roy Morgan M.D., Ph....
PDF
Feb 15, 2006 NEW YORK, NY - February 15, 2006 - ZIOPHARM Oncology, Inc. (OTC BB: ZIOP) announced today that Dr. Jonathan Lewis, Chief Executive Officer, will present at the Arch Investment Conference on Thursday, February 23, 2006 at 11:30 a.m. EST at Plaza Athenee Hotel in New York, NY. Dr. Lewis will provide an overview of the Company and an update on its...
PDF
Feb 9, 2006 NEW YORK, NY - February 9, 2006 - ZIOPHARM Oncology, Inc. (OTC BB: ZIOP), announced today a second organic arsenic case has been issued as U.S. Patent No. 6995188. The patent issue follows an announcement of a notice of allowance in mid-January. The patent provides further coverage of cancer treatment using organic arsenic, including ZIO-101,...
PDF
Jan 31, 2006 NEW YORK, NY - January 31, 2006 - ZIOPHARM Oncology, Inc. (OTC BB: ZIOP), announced today that ZIO-101, a novel and proprietary form of organic arsenic, has been administered to the first patient in a phase I/II trial in advanced myeloma. Interim data from an ongoing phase I trial suggest ZIO-101 can be given at significantly higher doses, wi...
PDF
Jan 19, 2006 NEW YORK, NY - January 19, 2006 - ZIOPHARM Oncology, Inc. (OTC BB: ZIOP) announced today the appointment of Barbara Wallner, Ph.D., as Senior Vice President, Technical Operations and Chief Technical Officer, reporting to Dick Bagley, President and Chief Operating Officer. Dr. Wallner will be located in the Company's Charlestown, MA office and...
PDF
Jan 17, 2006 NEW YORK, NY - January 17, 2006 - ZIOPHARM Oncology, Inc. (OTC BB: ZIOP), announced today it received a notice of allowance from the U.S. Patent and Trademark Organization in a second organic arsenic case, its first organic arsenic case having already issued. The allowed claims cover the treatment of cancer using organic arsenics, including ZIO...
PDF
Jan 9, 2006 NEW YORK, NY - January 09, 2006 - ZIOPHARM Oncology, Inc. (OTC BB: ZIOP), announced today the appointment of Robert Morgan, MS, JD, as Vice President of Regulatory Affairs and Quality, and Contract Counsel, reporting to Dick Bagley, President and Chief Operating Officer. He will be located in the Company's operational office in Charlestown, M...
PDF
Jan 6, 2006 NEW YORK, NY - January 06, 2006 - ZIOPHARM Oncology, Inc. (OTC BB: ZIOP) announced today that its company information will be made available via Standard & Poor's Market Access Program, an information distribution service that enables subscribing publicly traded companies to have their company information readily available and disseminated to...
PDF
Jan 4, 2006 NEW YORK, NY - January 4, 2006 - ZIOPHARM Oncology, Inc. (OTC BB: ZIOP), announced today it received approval from the FDA (U.S. Food and Drug Administration) to initiate a Phase I/II trial with one of its two lead products, ZIO-101, a novel organic arsenic, in patients with advanced myeloma. This announcement follows a similar approval for a...
PDF
Nov 21, 2005 NEW YORK, NY - November 21, 2005 - ZIOPHARM Oncology, Inc. (OTC BB: ZIOP) announced today the publication of an abstract on ZIO-201, a stabilized form of isophosphoramide mustard (IPM). The preclinical abstract is published and available online in Blood, the official journal of the American Society of Hematology. In abstract 4727 tit...
PDF
Page: FirstPrevious ...
40
NextLast